Layal Al Mahmasani - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Layal Al Mahmasani's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Layal Al Mahmasani
Verified
Advanced Oncology Fellow, Memorial Sloan Kettering Cancer-Center
New York
Beats
International affairs, Diplomacy, Energy, History, mysteries , true crime, business , military, investigations , global issues, homeland security , culture, Long-form, Weird news
Content
By Layal Al Mahmasani| Oncology Times Verified The treatment for hepatocellular carcinoma (HCC) has been evolving in the past 2 decades. The introduction of novel systemic therapies, including targeted therapies and immunotherapies, has transformed the treatment landscape, especially for patients with advanced disease. These advancements have resulted in unprecedented improvements in overall survival (OS) and outcomes.
Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report
By Layal Al Mahmasani, Noura Abbas, Panot Sainamthip, Mohamad Mourad| jgo.amegroups.org@ Highlight box Key findings • The combination of atezolizumab and bevacizumab for the treatment of a patient with hepatocellular carcinoma (HCC) and cardiovascular comorbidities led to complete radiological response but was associated with decrease in left ventricular ejection fraction necessitating discontinuation of bevacizumab. The patient maintained the good response on atezolizumab monotherapy until he passed away due to a presumed cardiac event. What is known and what is new?
By Layal Al Mahmasani| Oncology Times Verified The treatment for hepatocellular carcinoma (HCC) has been evolving in the past 2 decades. The introduction of novel systemic therapies, including targeted therapies and immunotherapies, has transformed the treatment landscape, especially for patients with advanced disease. These advancements have resulted in unprecedented improvements in overall survival (OS) and outcomes.
Company Info